Mizuho analyst Anthony Petrone raised the firm’s price target on DexCom (DXCM) to $100 from $95 and keeps an Outperform rating on the shares. The firm adjusted price targets in medical devices and diagnostics ahead of the Q2 reports.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on DXCM:
- DexCom price target raised to $89 from $82 at Morgan Stanley
- Wells says CBP proposal for CGMs expected, insulin pumps inclusion ‘a surprise’
- Diabetes device maker shares slide after payment scheduling proposal
- Diabetes stocks rally after RFK comments on HHS campaign
- Sweetgreen, Urogen, CoreWeave, Allegro, Dexcom: Trending by Analysts